MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • MDS Virtual Congress 2021

    Physical activity and cognitive functions in individuals with Parkinson’s disease

    APC. Loureiro, VL. Israel, B. Yamaguchi (Curitiba, Brazil)

    Objective: This study aimed to evaluate the relationship between physical activity and cognitive function in PD individuals. Background: Physical activity is positively associated with overall…
  • MDS Virtual Congress 2021

    Tele and video consultations of patients with parkinsonism in the Brazilian public health system – a real life feasibility study

    D. Dos Santos, D. Freire Camelo, M. Strelow, M. Silva, P. Führ, L. Marins, A. Schumacher-Schuh (Porto Alegre, Brazil)

    Objective: To evaluate the feasibility and identify obstacles in conducting teleconsultations for patients with parkinsonism in the Brazilian public health system Background: Patients with parkinsonism…
  • MDS Virtual Congress 2021

    Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease

    J. Peterschmitt, N. Giladi, R. Alcalay, G. Cutter, G. Höglinger, A. Schapira, C. Scherzer, T. Simuni, T. Gurevich, T. Gasser, C. Pacchetti, K. Marek, P. Minini, S. Sardi (Cambridge, USA)

    Objective: Report outcomes from Part 2 of the phase 2 MOVES-PD trial (NCT02906020) in patients with PD stratified by glucocerebrosidase (GBA) gene mutation severity. Background:…
  • MDS Virtual Congress 2021

    Causes of deaths in patients with Parkinson’s disease in the era before the use of modern drug therapy and at the present time

    S. Shtaimets (Omsk, Russian Federation)

    Objective: to study the impact of modern pharmacotherapy of Parkinson's disease (PD) on the main causes of death. Background: the modern era of the use…
  • MDS Virtual Congress 2021

    Hemiparkinsonism Due to Diencephalic Lesion with 24 Years of Levodopa Response and Only Mild Dyskinesia

    S. Filipović (Beograd, Serbia)

    Objective: To present a case of a long-standing hemiparkinsonism due to cerebral lesion with a continuous response to a stable dose of levodopa with only…
  • MDS Virtual Congress 2021

    A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson’s disease

    C. Fevga, Y. Park, E. Lohmann, A J. Kievit, G J. Breedveld, F. Ferraro, L. de Boer, R. van Minkelen, H. Hanagasi, A. Boon, W. Wang, G A. Petsko, Q Q. Hoang, M. Emre, V. Bonifati (Rotterdam, Netherlands)

    Objective: To report the identification of a novel variant in the gene encoding alpha-synuclein (SNCA), segregating with Parkinson’s Disease (PD) in two families of Turkish…
  • MDS Virtual Congress 2021

    Neurofilament light is related to fractional anisotropy in early Parkinson’s diesease

    T. Welton, Y. Tan, S. Saffari, N. Chia, S. Ng, Z. Lu, A. Yong, X. Choi, D. Heng, YC. Shih, S. Hartono, W. Lee, Z. Xu, K. Tay, WL. Au, EK. Tan, LL. Chan, A. Ng, L. Tan (Singapore, Singapore)

    Objective: We aimed to determine whether plasma NfL reflects changes in brain white matter integrity as measured using fractional anisotropy (FA) in patients with early…
  • MDS Virtual Congress 2021

    Apathy: an underestimated feature in premotor period of GBA and LRRK2 non-manifesting mutation carriers.

    I. Pachi, C. Koros, A. Simitsi, D. Papadimitriou, A. Bougea, A. Prentakis, N. Papagiannakis, M. Bozi, R. Antonelou, E. Angelopoulou, I. Beratis, M. Stamelou, X. Trapali, S. Papageorgiou, L. Stefanis (Athens, Greece)

    Objective: The aim was to detect the differences between GBA and LRRK2 mutation carriers without Parkinson’s disease and healthy controls (HC) on neuropsychiatric symptoms. Background:…
  • MDS Virtual Congress 2021

    Parkinson’s Disease Functional Impacts Digital Instrument (PD-FIDI): Studies Preceding Clinical Validation

    A. Pearlmutter, N. Wong, M. Levin, R. Zheng, R. Ellis, P. Kelly, M. Peterschmitt (Cambridge, USA)

    Objective: Summarize the findings from 3 developmental studies of the Parkinson’s Disease Functional Impacts Digital Instrument (PD-FIDI) – a novel endpoint for assessing PD symptoms.…
  • MDS Virtual Congress 2021

    Determining the content of a clinician-rated tool for freezing of gait severity

    A. Scully, B. de Oliveira, K. Hill, D. Tan, YH. Pua, R. Clark, E. Burton (Bentley, Australia)

    Objective: This study aimed to determine clinician’s ratings of the most important triggering circumstances to be examined and aspects of freezing of gait (FOG) to…
  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley